Latest Stocks: Alnylam Pharmaceuticals, Inc. (ALNY) Stock Rating Reaffirmed by Credit Suisse Group AG

Latest Stocks: Alnylam Pharmaceuticals, Inc. (ALNY) Stock Rating Reaffirmed by Credit Suisse Group AG

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)‘s stock had its “outperform” rating reaffirmed by analysts at Credit Suisse Group AG in a research report issued to clients and investors on Wednesday, May 17th. They presently have a $90.00 target price on the biopharmaceutical company’s stock, up from their previous target price of $50.00. Credit Suisse Group AG’s price target would suggest a potential upside of 28.70% from the stock’s previous close.

Several other equities research analysts have also recently commented on ALNY. Ladenburg Thalmann Financial Services initiated coverage on Alnylam Pharmaceuticals in a report on Thursday, February 2nd. They set a “buy” rating and a $75.00 target price on the stock. JMP Securities set a $69.00 target price on Alnylam Pharmaceuticals and gave the stock a “buy” rating in a report on Friday, February 3rd. Vetr cut Alnylam Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $46.77 target price on the stock. in a report on Monday, February 6th. Needham & Company LLC reissued a “buy” rating and set a $68.00 target price (down previously from $98.00) on shares of Alnylam Pharmaceuticals in a report on Thursday, February 9th. Finally, FBR & Co reissued an “outperform” rating on shares of Alnylam Pharmaceuticals in a report on Tuesday, March 7th. Two equities research analysts have rated the stock with a sell rating, six have issued a hold rating and twelve have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $70.50.

Shares of Alnylam Pharmaceuticals (ALNY) opened at 69.93 on Wednesday. The company’s market capitalization is $6.03 billion. Alnylam Pharmaceuticals has a 52 week low of $31.38 and a 52 week high of $80.11. The firm’s 50-day moving average is $60.18 and its 200 day moving average is $49.28.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its earnings results on Friday, May 5th. The biopharmaceutical company reported ($1.25) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.22) by $0.03. Alnylam Pharmaceuticals had a negative return on equity of 37.25% and a negative net margin of 869.63%. The firm had revenue of $19 million for the quarter, compared to the consensus estimate of $22.91 million. During the same period in the previous year, the firm earned ($1.21) EPS. Alnylam Pharmaceuticals’s revenue for the quarter was up 160.3% on a year-over-year basis. On average, analysts anticipate that Alnylam Pharmaceuticals will post ($5.31) earnings per share for the current fiscal year. In other news, EVP Akshay Vaishnaw sold 11,000 shares of the business’s stock in a transaction on Tuesday, May 23rd. The shares were sold at an average price of $75.00, for a total transaction of $825,000.00. Following the transaction, the executive vice president now directly owns 21,297 shares in the company, valued at approximately $1,597,275. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, VP Michael Mason sold 9,375 shares of the business’s stock in a transaction on Tuesday, May 16th. The shares were sold at an average price of $70.00, for a total transaction of $656,250.00. Following the transaction, the vice president now owns 5,625 shares in the company, valued at $393,750. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 64,125 shares of company stock worth $4,325,000. Corporate insiders own 4.00% of the company’s stock.

Institutional investors have recently bought and sold shares of the stock. Janus Capital Management LLC boosted its position in Alnylam Pharmaceuticals by 25.5% in the first quarter. Janus Capital Management LLC now owns 649,399 shares of the biopharmaceutical company’s stock valued at $33,280,000 after buying an additional 131,969 shares in the last quarter. Credit Suisse AG boosted its position in Alnylam Pharmaceuticals by 39.0% in the first quarter. Credit Suisse AG now owns 248,364 shares of the biopharmaceutical company’s stock valued at $12,729,000 after buying an additional 69,697 shares in the last quarter. Blue Ridge Capital L.L.C. boosted its position in Alnylam Pharmaceuticals by 20.5% in the first quarter. Blue Ridge Capital L.L.C. now owns 1,590,000 shares of the biopharmaceutical company’s stock valued at $81,488,000 after buying an additional 270,000 shares in the last quarter. Perceptive Advisors LLC boosted its position in Alnylam Pharmaceuticals by 831.4% in the first quarter. Perceptive Advisors LLC now owns 1,103,475 shares of the biopharmaceutical company’s stock valued at $56,553,000 after buying an additional 985,000 shares in the last quarter. Finally, KCG Holdings Inc. boosted its position in Alnylam Pharmaceuticals by 8.1% in the first quarter. KCG Holdings Inc. now owns 31,800 shares of the biopharmaceutical company’s stock valued at $1,630,000 after buying an additional 2,374 shares in the last quarter. Institutional investors and hedge funds own 88.70% of the company’s stock. Alnylam Pharmaceuticals Company Profile

Related posts

Leave a Comment